Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 29;20(17):4224.
doi: 10.3390/ijms20174224.

Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment

Keiko Yamakawa  1 , Yuko Nakano-Narusawa  1 , Nozomi Hashimoto  1 , Masanao Yokohira  1 , Yoko Matsuda  2
Affiliations
Review

Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment

Keiko Yamakawa et al. Int J Mol Sci. .

Abstract

Approximately 30% of pancreatic cancer patients harbor targetable mutations. However, there has been no therapy targeting these molecules clinically. Nucleic acid medicines show high specificity and can target RNAs. Nucleic acid medicine is expected to be the next-generation treatment next to small molecules and antibodies. There are several kinds of nucleic acid drugs, including antisense oligonucleotides, small interfering RNAs, microRNAs, aptamers, decoys, and CpG oligodeoxynucleotides. In this review, we provide an update on current research of nucleic acid-based therapies. Despite the challenging obstacles, we hope that nucleic acid drugs will have a significant impact on the treatment of pancreatic cancer. The combination of genetic diagnosis using next generation sequencing and targeted therapy may provide effective precision medicine for pancreatic cancer patients.

Keywords: antisense oligonucleotide; clinical trial; nucleic acid medicine; pancreatic cancer; siRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Delivery of nucleic acid medicines. (1) Intravenous injection, (2) intratumoral injection under EUS, and (3) intratumoral implantation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torres C., Grippo P.J. Pancreatic cancer subtypes: A roadmap for precision medicine. Ann. Med. 2018;50:277–287. doi: 10.1080/07853890.2018.1453168. - DOI - PMC - PubMed
    1. Gleeson F.C., Kerr S.E., Kipp B.R., Voss J.S., Minot D.M., Tu Z.J., Henry M.R., Graham R.P., Vasmatzis G., Cheville J.C., et al. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Oncotarget. 2016;7:54526–54536. doi: 10.18632/oncotarget.9440. - DOI - PMC - PubMed
    1. Barata P., Sood A.K., Hong D.S. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat. Rev. 2016;50:35–47. doi: 10.1016/j.ctrv.2016.08.004. - DOI - PubMed
    1. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer—The time of truth. Lancet Oncol. 2002;3:672–683. doi: 10.1016/S1470-2045(02)00903-8. - DOI - PubMed
    1. Moreno P.M., Pego A.P. Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic. Front. Chem. 2014;2:87. doi: 10.3389/fchem.2014.00087. - DOI - PMC - PubMed

MeSH terms